Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines-Reference-Cited by-同舟云学术

Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines

Published:2023-02 Issue:1 Volume:8 Page:100604
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Zarkavelis G.,Amylidi A.L.,Verbaanderd C.,Cherny N.I.,Metaxas Y.,de Vries E.G.E.,Zygoura P.,Amaral T.,Jordan K.,Strijbos M.,Dafni U.,Latino N.,Galotti M.,Lordick F.,Giuliani R.,Pignatti F.,Pentheroudakis G.

Funder

European Society for Medical Oncology

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference59 articles.

1. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study;Arnold;Lancet Oncol,2019

2. Off-label drug use in oncology: a systematic review of literature;Saiyed;J Clin Pharm Ther,2017

3. The off-label use of antineoplastics in oncology is limited but has notable scientific support in a university hospital setting;Fernandez;Front Pharmacol,2019

4. The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO);Casali;Ann Oncol,2007

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How to develop new systemic treatments in ultra-rare cancers with high unmet needs? The case of alveolar soft-part sarcoma;European Journal of Cancer;2024-05

2. Real‐world treatment outcomes of immune checkpoint inhibitors used off‐label in oncology: A comprehensive cancer institution experience;Pharmacology Research & Perspectives;2024-01-09

3. Real‐world treatment outcomes of medicines used in special situations (off‐label and compassionate use) in oncology and hematology: A retrospective study from a comprehensive cancer institution;Cancer Medicine;2023-07-26

4. Efficacy of Off-Label Use of Anticancer Drugs in Oncology;Creative surgery and oncology;2023-06-30

5. Comments on “Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines”;ESMO Open;2023-06